drugset / Trial / NCT03836937

Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT

NCT03836937

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted upon the patients with fatty liver disease. Patients who will be diagnosed as a case of fatty liver disease by ultrasound with raised liver enzyme (ALT) will be primarily selected for the study. A total number of 70 patients will be randomly selected for the study that will also be divided into two groups for the study purpose. The patients will be informed about the details of the study. After getting the detail information those who will give informed written consent will be finally included in the study. One group of patients will be treated by both life style modification and Obeticholic acid. Another group of patients by only life style modification. After 3 months of treatment the two groups will be compared of improvement of fatty liver disease and liver enzyme by improvement of fibroscan with CAP value as well as improvement of ALT value.

Timeline

Start
2019-03-05
Primary completion
2020-11-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Obeticholic Acid Small molecule 10 mg

Indications